Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $256.96 USD
Change Today -0.34 / -0.13%
Volume 935.4K
VRX On Other Exchanges
As of 12:11 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Robert Roswell Chai-Onn

Chief Legal Officer, Executive Vice President, Head of Corporate & Business Development and General Counsel, Valeant Pharmaceuticals International, Inc.
AgeTotal Calculated CompensationThis person is connected to 12 board members in 5 different organizations across 7 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. Robert Roswell Chai-Onn has been General Counsel, Executive Vice President, and Secretary at Salix Pharmaceuticals Ltd., since April 2015. Mr. Chai-Onn has been Head of Corporate & Business Development and Chief Legal Officer at Valeant Pharmaceuticals International, Inc. since January 10, 2014 and its Executive Vice President, General Counsel and Corporate Secretary since September 2010. He served as Secretary of Solta Medical, Inc. since January 23, 2014. He served ...

Read Full Background

Corporate Headquarters*

2150 St. Elzéar boulevard West
Laval, Quebec H7L 4A8


Phone: 514-744-6792
Fax: 514-744-6272

Board Members Memberships*

Executive Officer and Director
Secretary and Director
Secretary and Director
General Counsel, Executive Vice President, Secretary and Director


Bachelor's Degree
Yale University
Master's Degree
University of Cambridge
School Of Law, Columbia University

Other Affiliations*

Annual Compensation*

Total Annual Compensation$715,385

Stock Options*

Restricted Stock Awards$21,389,884
All Other Compensation$26,978
Exercised Options25,203
Exercised Options Value$1,852,200
Exercisable Options377,363
Exercisable Options Value$45,141,750
Unexercisable Options154,286
Unexercisable Options Value$5,649,953
Total Value of Options$52,643,903
Total Number of Options556,852

Total Compensation*

Total Annual Cash Compensation$2,542,363
Total Short Term Compensation$715,385
Other Long Term Compensation$21,416,862
Total Calculated Compensation$23,932,247
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:US $256.88 USD -0.42


Giovanni Caforio M.D.Chief Executive Officer and Director
Bristol-Myers Squibb Company
Miles D. White Chairman, Chief Executive Officer and Chairman of Executive Committee
Abbott Laboratories
Robert J. Hugin MBAChairman, Chief Executive Officer and Chairman of Executive Committee
Celgene Corporation
John C. Lechleiter Ph.D.Chairman, Chief Executive Officer and President
Eli Lilly and Company
Yoshihiko Hatanaka Chief Executive Officer, President and Representative Director
Astellas Pharma, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at